Fusion Antibodies (LON:FAB) Shares Up 4.8% – Should You Buy?

Fusion Antibodies plc (LON:FAB) shot up 4.8% during mid-day trading on Wednesday . The stock traded as high as GBX 11 and last traded at GBX 11. 178,112 shares traded hands during mid-day trading, a decline of 57% from the average daily volume of 415,618 shares. The stock had previously closed at GBX 10.50.

Fusion Antibodies Price Performance

The stock has a 50 day moving average of GBX 11.37 and a 200-day moving average of GBX 12.81. The company has a debt-to-equity ratio of 92.42, a quick ratio of 2.36 and a current ratio of 1.80. The company has a market cap of £13.77 million, a PE ratio of -7.33 and a beta of 1.22.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.